onists (H1 antihistamines) are one of the most commonly prescribed medications for the treatment of AR. There are several oral H1 antihistamines available and it is important to know the pharmacology, such as administration interval, onset of action, metabolism and conditions that require administration adjustments. When prescribing oral H1 antihistamines, the healthcare provider must take into account the clinical efficacy and weigh this against the risk of adverse effects from the agent. In addition to the clinical efficacy, potential for improvement in QOL with a particular treatment should also be considered.
Allergic rhinitis (AR) is now recognised as a posed of a panel of experts in conjunction with the global health problem that affects 10-30% of adults WHO, have proposed a new classification for AR. [5] and up to 40% of children. [1] Each year, there are These guidelines were intended to educate healthmillions of office visits for AR and its complica-care providers and aid in the diagnosis and treatment tions, such as sinus disease and otitis media with of AR on the basis of symptom duration and severieffusion. However, the prevalence of AR may be ty. However, it was shown that the classic types of underestimated because of misdiagnosis, under di-seasonal and perennial rhinitis cannot be used interagnosis and failure of patients to seek medical atten-changeably with the new classification of intermittion. [2] [3] [4] tent/persistent, because they do not represent the same stratum of disease.
[4] Furthermore, to date all AR is a disorder of the nasal tissue caused by clinical trials have utilised SAR and PAR. IgE-mediated inflammation and manifests clinically as sneezing, itching, rhinorrhoea and nasal obstrucTreatment of AR includes avoidance of allergic tion. [3, 5] Ocular symptoms including pruritus, oede-triggers, the use of pharmacological agents and alma and lacrimation are also commonly associated lergen specific immunotherapy. There are numerous with AR. In addition to the classical symptoms, it is pharmacological agents available to help control now recognised that AR has a significant impact on AR. These include oral first-and second-generation the quality of life (QOL) of those who experience it. histamine H1 receptor antagonists (H1 antihista-A major condition commonly encountered as a re-mines), intranasal antihistamines, intranasal corticosult of AR is sleep disturbance. Failure to get a good steroids, leukotriene receptor antagonists, mast cell night's sleep as a result of symptoms of AR can stabilisers, intranasal anticholinergics, and oral and cause significant impairment in daily activities such intranasal decongestants. Oral H1 antihistamines as work and school. [1, 6, 7] The vast majority of pa-and intranasal corticosteroids are recommended as tients with asthma have AR. Several studies have first-line therapy. [1, 2, 5, 11] This review focuses on oral also shown severe rhinitis symptoms in patients with H1 antihistamines and helps to guide the healthcare asthma was associated with worse asthma out-provider in selecting the most appropriate oral H1 comes. [8] [9] [10] antihistamine based on favourable effects including rapid onset of action, low potential for drug interacTraditionally, AR has been subdivided into seation and improvements in QOL and avoidance of sonal AR (SAR) or perennial AR (PAR). SAR undesired side effects such as sedation and dry symptoms usually appear during a specific season in mouth. which aeroallergens are present in the outdoor air such as tree and grass pollen in the spring and summer and weed pollens in the autumn (fall); and 1. Pathophysiology of Allergic Rhinitis PAR symptoms are present year-round and are triggered by dust mite, animal dander, indoor molds and
The tendency to develop a T helper type 2 (Th2) cockroaches. [3] The recent Allergic Rhinitis and its cell immune response is inherited in atopic paImpact on Asthma (ARIA) recommendations, com-tients. [3] Sensitisation to specific inhalant allergens occurs when they are presented by antigen present-to IgE on the cell surface and crosslinking FcεRI (a ing cells to CD4+ T cells that belong to the Th2 high-affinity receptor for IgE). [16] Histamine then subset, leading to the production of interleukin acts in the nose to cause vasodilatation and in-(IL)-3, IL-4, IL-5, IL-13 and other Th2 cytokines. creased vascular permeability, and stimulation of These cytokines stimulate B cells to become plasma sensory nerves leading to the sensation of itching. cells, which produce IgE specific for that allergen. This manifests clinically as sneezing, rhinorrhoea The IgE then binds to high affinity IgE receptors on and pruritus. [17] There are at least four types of mast cells and basophils. Upon re-exposure to the histamine receptors that have been identified. Howspecific allergen, it binds to the IgE on mast cells ever, the majority of allergic responses are mediated and basophils and starts a cascade of events leading via the H1 receptor. [16] The second-generation H1 to the symptoms of AR. The allergic response in AR antihistamines have very high avidity and selectivity can be subdivided into the acute or early phase and for H1 receptors.
[18-21] H1 antihistamines are inverse the late phase.
agonists that combine with and stabilise the inactive form of the H1 receptor leading toward a shift in
Early Phase
equilibrium to the inactive state. [22, 23] In addition to antagonising histamine at the H1 receptor, the newer Allergen binds to IgE on mast cells which causes second-generation agents have both antiallergic and these cells to degranulate and release pre-formed anti-inflammatory properties. They have been inflammatory mediators such as histamine, tryptase, shown to inhibit the release of mediators from mast chymase, heparin and other enzymes. [3, 12] In addicells and basophils through a direct inhibitory effect tion to the preformed mediators, mast cells also on calcium-ion channels.
[24] Pretreatment with an H1 synthesise mediators de novo such as prostaglandin antihistamine has been shown to decrease the early (PG)D2, cysteinyl leukotrienes (LTC4, LTD4 and response to an allergen challenge through decreas-LTE4) and platelet activating factor (PAF). [2, 3, 13] ing the levels of proinflammatory cell adhesion molHistamine is a prominent mediator of the early ecules, cytokines, mediators such as histamine, phase resulting in vascular leakage via H1 receptors leukotrienes and prostaglandins.
[ [25] [26] [27] and stimulation of nerve endings, thus resulting in the symptoms of rhinorrhoea, sneezing and nasal 2.1 First-Generation Oral Antihistamines pruritus. [2, 3] The older first-generation H1 antihistamines such
Late Phase
as diphenhydramine, chlorphenamine (chlorpheniThe late-phase response occurs several hours af-ramine), brompheniramine and hydroxyzine are also ter the early phase. It involves cellular infiltration of referred to as the sedating antihistamines. These eosinophils, basophils, T cells, neutrophils and mac-agents are effective at controlling the rhinorrhoea, rophages into the nasal tissue. [14, 15] These cells re-sneezing and pruritus associated with AR. However, lease cytokines and other inflammatory mediators because these older agents cross the blood-brain leading to a clinically similar response to the early barrier they are associated with significant adverse phase. Eosinophil-derived mediators such as major effects, such as sedation leading to impaired perbasic protein, eosinophil cationic protein and leuko-formance at home, work and school. [1, 28] Even when trienes have been shown to distort the epithelium first-generation antihistamines are taken at bedtime, ultimately leading to chronic allergic inflamma-they may still cause significant residual daytime tion. [3] sedation, decreased alertness and performance impairment. [28] These agents have poor H1-receptor 2. Pharmacology selectivity and act on muscarinic receptors causing Histamine is primarily produced by mast cells anticholinergic effects such as dry mouth, urinary and basophils, and is released upon antigen binding retention, constipation and tachycardia. [1, 29, 30] The high risk to benefit ratio makes the first-generation such as exposure unit and pollen chamber studies H1 antihistamines a less attractive therapeutic option and unique outcome measures such as measuring and they are not recommended as first-line therapy nasal airflow obstruction or patient symptom rein AR.
cording. [42] One method that has become increasingly important in efficacy trials is assessment of 2.2 Second-Generation Oral Antihistamines QOL. [43] Several controlled trials of second-generation H1 antihistamines have been published and The newer second-generation H1 oral antihistahave shown overall relief of symptoms reported by mines were first developed in the early 1980s to patients. [42, Notably, all clinical trials that have improve on the sedative and anticholinergic adverse been published to date assessing second-generation effects in the first-generation agents. The second-H1 antihistamines in the treatment of AR have been generation antihistamines have improved H1-recepon patients with SAR and PAR and not intermittent tor selectivity, absence or decreased sedation, faster AR or persistent AR.
[5] Examination of these trials onset and longer duration of action and fewer adhas lead to several conclusions: (i) the overall effecverse effects.
[13,31] The currently available secondtiveness of second-generation antihistamines for generation H1 antihistamines are shown in table I. symptomatic treatment of AR was quite good; (ii) Most second-generation H1 antihistamines have patient acceptance and overall satisfaction was been shown to have antiallergic and anti-inflammagood; and (iii) adverse effects were mild.
[62] Several tory properties in vivo or in vitro.
clinical trials assessing QOL in patients with AR In general, second-generation antihistamines ex-have also been reported. Overall, treatment with hibit favourable pharmacokinetics.
[32] They have a second-generation antihistamines consistently imrelatively quick onset of action, near complete ab-proves QOL. sorption, widespread tissue distribution with minimal CNS penetration, unlike first-generation anti-
Cetirizine
histamines, and relatively long half-life allowing for Cetirizine, a metabolite of hydroxyzine, exists once-daily administration.
[33] The pharmacodynam-mainly as a zwitterion allowing for low volume of ics and pharmacokinetics of second-generation anti-distribution, low serum concentration and a dehistamines are summarised in table II.
[34-40] The creased affinity for myocardium with decreased risk second-generation H1 antihistamines have a similar for cardiotoxicity.
[76] Cetirizine is rapidly absorbed core moiety, but it is the radicals or side chains and achieves peak plasma concentration in ≈1 hour. adjoining the core which determine the absorption, In addition to H1 receptor antagonism, cetirizine distribution and elimination of each agent. [41] was found to inhibit eosinophil chemotaxis during It is rather difficult to study the clinical effective-the allergic response and, therefore, blunted the lateness of AR treatment because of the variability that phase reaction. [77] is associated with the disorder. Therefore, several
Cetirizine is the only second-generation H1 antistandardised methods have been developed to objec-histamine to cause an increased incidence of sedatively assess the clinical efficacy of AR treatment tion at its recommended dose in patients ≥12 years of age. [78] Therefore, cetirizine is classified as mildly sedating and should not be prescribed to patients whose jobs require high psychomotor skills such as pilots. [79] Cetirizine has been shown in numerous clinical trials to be more efficacious compared with placebo in the treatment of both SAR and PAR. [46] [47] [48] [49] [50] 80] Cetirizine significantly improved QOL measures of general health, physical functioning, vitality, social functioning, and emotional and b Not available in the US at the time of publication. bid = twice daily; t1/2 = elimination half-life; tmax = time after dose to reach maximum plasma concentration.
mental health within 1 week of treatment and con-hibit intercellular adhesion molecule 1 expression tinued up to 6 weeks.
[81] In a small but similar study, on nasal epithelium in vitro.
[82]
cetirizine improved QOL measures compared with Numerous clinical trials have shown fexofenaplacebo. [80] dine to be more efficacious than placebo for the symptoms of SAR. [64] [65] [66] [67] [68] [69] [70] Fexofenadine is approved for use in the US for SAR but not PAR. [87] Van
Loratadine
Cauwenberge et al. [71] conducted a large, multinaLoratadine has been found to exert protective tional, double-blind, placebo-controlled, 2-week trieffects on the early and late phase of conjunctival al of fexofenadine (120mg once daily) versus allergic reactions. [26, 82] Loratadine is a nonsedating loratadine (10mg once daily) in patients with SAR. antihistamine, and psychomotor tests confirm its Individual symptoms were self-assessed and no difsafety at the recommended dosage (10 mg/day). [83] ference in overall symptom scores was observed However, performance studies with higher, off-label between fexofenadine and loratadine. However, fexloratadine doses of 20 and 40mg showed significant ofenadine significantly improved the individual impairment and sedation in some objective performsymptoms of nasal congestion and itchy, watery, red ance tests compared with placebo. [84] eyes compared with loratadine. Fexofenadine was Although the placebo-controlled studies with found to decrease work impairment and benefit loratadine are limited, two studies [74, 75] have shown emotions, sleep and practical problems. [69] that loratadine was superior to placebo in the treatment of AR.
Desloratadine

Fexofenadine
Desloratadine is the active metabolite of Fexofenadine, the active metabolite of loratadine and is approved for use in children ≥12 terfenadine, is a potent H1 receptor antagonist that years of age for both SAR and PAR. [88] Desloratadoes not display cardiotoxicity like its predeces-dine has the greatest avidity for the H1 receptor, sor. [85] In addition to blocking H1 receptors, in vitro although poor selectivity. [18] Desloratadine has been and in vivo studies have shown that fexofenadine shown to inhibit IgE mediated and non-IgE medireduces allergic inflammatory responses mediated ated release of IL-4 and IL-13 from human basoby mast cells, basophils, epithelial cells, eosinophils phils in vitro. [27] Like loratadine, desloratadine sigand lymphocytes. [71, 86] Fexofenadine has proven an-nificantly reduces the symptoms of SAR. However, ti-inflammatory activity and has been shown to in-as in the case of loratadine (see section 2.2.2), somnolence has been noted at higher, off-label All three drugs provided significant improvement in doses. [35, 84, 89, 90] nasal peak inspiratory flow compared with placebo with no differences between them. Several clinical Desloratadine has been shown in several studies have shown that cetirizine and fexofenadine randomised, clinical trials to significantly improve were significantly more efficacious than placebo in patients symptoms. [60, 61] Two, randomised, doublethe treatment of SAR with no difference between blind, multicentre studies comparing the efficacy of them; [52] [53] [54] however, fexofenadine produced less desloratadine with placebo showed a statistically drowsiness. [54] It should be noted that both SAR and significant reduction in symptoms in patients with PAR often coexist in study participants thus making SAR over a 2-week study period. [60] Desloratadine it difficult to interpret the results of these clinical treatment of SAR resulted in improvement of social trials. functioning and symptoms. [59] Desloratadine rapidly and safely reduced the symptoms of PAR, and its 3. Adverse Effects efficacy did not diminish during 4 weeks of treatment. [91] However, no large clinical trials studying First-generation antihistamines have the greatest the effect of desloratadine on QOL have been re-potential for serious adverse effects. There are no ported. [40] long-term safety studies on the first-generation anti-
Levocetirizine
histamines. These older antihistamines have potential for serious adverse effects such as CNS, depresLevocetirizine is the enantiomer of cetirizine.
sion and cardiotoxicity, and have also been associatLevocetirizine, like cetirizine, exists as a zwitterion ed with fatalities in accidental and intentional and, thus, has a lower volume of distribution and paediatric overdose. [95] [96] [97] In contrast, second-generalso has been shown to inhibit eotaxin-induced tranation antihistamines are relatively free of adverse sendothelial migration of eosinophils in vitro. [77, 90] effects and are generally well tolerated. The most Levocetirizine, like cetirizine, is also considered prevalent adverse effects associated with secondmildly sedating in placebo-controlled trials. [92] A generation antihistamines reported by the manufacrandomised trial involving >400 patients with SAR turers from large-scale clinical trials are shown in found that levocetirizine significantly reduced  table III. [78, 87, 88, 92, 98] symptom scores over an 8-week period. A large, multicentre study in children with SAR and PAR
CNS Effects
found that 4-6 weeks of treatment with levocetirizine significantly improved symptoms and Undesirable effects of antihistamines include se-QOL.
[93] A multinational, placebo-controlled study dation and impairment, and depend on the ability of recently found that levocetirizine significantly im-the drug to cross the blood-brain barrier and bind to proved QOL over 6 months of treatment. [5] central H1 receptors. The second-generation antihis-
Comparative Studies
tamines, also referred to as nonsedating, have a decreased tendency to cross the blood-brain barri-A double-blinded, placebo-controlled, parallel er. [99] Consequently, second-generation antihistagroup study comparing fexofenadine, loratadine or mines are respected for their low potential to cause placebo in the treatment of SAR showed that both CNS effects. fexofenadine and loratadine were superior to placebo in patient symptom scores; however, fexSeveral studies have been conducted to assess the ofenadine decreased the scores for itchy, watery, red severity and magnitude of CNS depression that eyes and nasal congestion more than loratadine. [71] these drugs can cause. The majority of these studies Lee at al. [94] conducted a crossover study comparing focused on subjective and objective measures of the protective effect of single doses of levoce-sedation such as: sleepiness/wakefulness scores, tirizine, desloratadine and fexofenadine against sleep latency, EEG changes, driving ability, learnadenosine monophosphate in 16 patients with PAR. ing/school performance and memory. Studies in- volving first-generation antihistamines have consist-US market because of their cardiotoxic effects at ently shown significantly greater effects on sedation increased plasma concentrations caused by drugscores, psychomotor test performance and cognitive drug interactions. [35] Currently, no clinically signififunction compared with second-generation H1 anti-cant cardiotoxic effects have been reported for histamines.
[89,100-109] Therefore, second-generation loratadine, desloratadine, fexofenadine, cetirizine antihistamines are generally preferred over first-and levocetirizine. [40, 81, 113] generation antihistamines especially for people whose jobs require a high level of psychomotor 4. Drug Interactions skills.
Drug-drug interactions usually occur as a result Multiple studies have evaluated the effects that of altered metabolism in the hepatic cytochrome second-generation antihistamines have on the CNS. P450 (CYP) system or through interference with Loratadine and desloratadine were found to be comabsorption via active transport mechanisms such as parable with placebo at therapeutic doses, but P-glycoprotein and organic-anion transporters. [13, 35] caused sedation when used off label at higher than Loratadine and desloratadine undergo CYP metaborecommended doses. [35, 42, 84, 89] Several studies have lism like terfenadine and astemizole, which are no shown that cetirizine, given at therapeutic doses, longer on the market. [35, 40, 42] Therefore, loratadine causes a slight to moderate increase in sedation, and desloratadine are more susceptible to altered decreased psychomotor function and worsening plasma concentrations when taken in conjunction cognitive function. [102] [103] [104] [105] [106] [107] [108] In contrast, fexofenadine with other medications that are metabolised via the has been found to be free of sedative effects even at CYP system. Conversely, fexofenadine, cetirizine higher than therapeutic doses. [84, 89, 110] Memory, atand levocetirizine are not metabolised by the tention and tracking performance were unaffected CYP450 system, which makes them less susceptible after administration of levocetirizine compared with to interactions involving this mechanism.
[35, 40, 42] diphenhydramine and placebo. [111] However, they still remain susceptible to interactions involving P-glycoprotein and organic-anion 3.2 Cardiotoxicity active transport mechanisms. The potential for H1 antihistamines to produce Fexofenadine is a substrate for P-glycoprotein, cardiotoxicity is directly related to their plasma con-which is a membrane-bound transporter that inhibits centration and, therefore, appropriate administration absorption and promotes excretion. [114] Grapefruit and drug-drug interactions are important. The first-juice has been found in vitro to inhibit P-glycoprotegeneration antihistamines have been found to pro-in activity. [115] Therefore, when consumed with long the QT interval at higher than recommended grapefruit juice, the plasma concentration of fexdoses. [112] Terfenadine and astemizole, both second-ofenadine can be decreased by up to 40%. [116] This is generation antihistamines, were withdrawn from the thought to be caused by inhibition of the organic tential for adverse effects. [87, 113] It is important to 
